Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...
Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung ...
The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...
Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded ...
Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...
In idiopathic pulmonary fibrosis, 12 months of pulmonary rehabilitation increased cerebral oxygenation during exercise, ...
A hybrid model combining LM, GA, and BP neural networks improves TCM's diagnostic accuracy for IPF, achieving 81.22% ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jeffrey J. Swigris ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback